The Journal of Virus Eradication is a new open-access online and print journal dedicated to the rapidly developing field of virus eradication. It is particularly interested in publishing original research on HIV, hepatitis viruses, HPV, herpes and flu but work on other viruses is also included. The first issue was successfully launched at the HIV and Hepatitis Five Nations Conference in London
on 8 December 2014 and is available now on the Journal website: www.viruseradication.com
23 December 2014 | Mediscript
There is a virus that is 100 times more easily transmitted than the dreaded acquired immunodeficiency syndrome virus, and it is called Hepatitis B Virus (HBV). HBV is a virus that can cause Chronic Hepatitis B, a life threatening liver disease. According to United States Center for Disease Control and Prevention (CDC), up to 25 percent of people with chronic hepatitis B develop serious liver problems such as liver failure, liver cancer and cirrhosis (severe liver scarring), if left untreated.One in 10 Asian Americans has HBV- a rate over 20 times higher than that of the overall U.S. population - two in three of whom are not aware of it.
27 August 2014 | Philippine Star
Lei Chuang trekked almost 1,000 miles over 80 days from Shanghai to Beijing last summer, along riverbanks and highways, to deliver a petition beseeching China’s leaders to cut the prices of hepatitis B drugs. “If drug companies can afford such huge sums for bribing doctors and hospitals, then they should still be profitable if prices are lowered by 50 percent,” said Guangzhou-based Lei, nicknamed the “Hepatitis B Warrior” by Chinese media. “They could use that money to benefit patients instead.”
30 May 2014 | Bloomberg
In a written answer to a parliamentary question, Health Minister Norman Lamb said the number of prisoners diagnosed with chronic forms of the virus has risen from just 22 in 2010 to 109 in 2013.
01 May 2014 | The Independent
Three antiretrovirals that also help control hepatitis B virus (HBV) infection—tenofovir, emtricitabine, and lamivudine—may also prevent HBV infection, according to results of a retrospective analysis involving men who have sex with men (MSM) in the Netherlands.
24 April 2014 | International AIDS Society
Previous research indicates people with HIV have a reduced immune response to most vaccines, but how does immune response hold up over time—and what are the implications for re-vaccinating with “booster shots”?
26 January 2014 | BETA blog
Job applicants and students are regularly turned down on the basis of the disease. Now, some are fighting back.
04 December 2013 | The Atlantic
A team of researchers has identified a novel mutation in the hepatitis B virus (HBV) in Korea that appears only in men and could help explain why HBV-infected men are roughly five times more likely than HBV-infected women to develop liver cancer. Although some women do progress to cirrhosis and liver cancer, the mutation is absent in HBV in women. The research is published ahead of print in the Journal of Clinical Microbiology.
18 October 2013 | Eurekalert Inf Dis
A universal infant vaccination campaign in China has led the hepatitis B virus to more than double its rate of "breakout" mutations. These mutations may enable the virus to elude the vaccine, necessitating new vaccination strategies.
08 October 2013 | Eurekalert Medicine & Health
The U.S. Food and Drug Administration (FDA) announced this week that it has approved labeling changes for 2 monoclonal antibody cancer drugs, ofatumumab (Arzerra) and rituximab (Rituxan), adding a stronger "black box" warning that they may cause hepatitis B virus (HBV) reactivation.
30 September 2013 | HIVandhepatitis.com